InMed Pharmaceutical

IN
Delayed Toronto Stock Exchange - 04/03 09:55:43 pm
0.205CAD
-6.82%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Number of employees : 12 people.
Managers
Name Title
Eric A. Adams President, Chief Executive Officer & Director
William J. Garner Chairman
Bruce S. Colwill Chief Financial Officer
Adam Daniel Cutler Independent Director
Andrew Hull Independent Director
Catherine A. Sazdanoff Director
Eric C. Hsu Vice President-Preclinical Research & Development
Michael Woudenberg VP-Chemistry, Manufacturing & Controls
Alexandra D. J. Mancini Senior VP-Clinical & Regulatory Affairs
Shareholders
Name Equities %
Paul Chow 3,642,937 2.11%
Sazzad Hossain 2,657,500 1.54%
Andrew Hull 625,000 0.36%
Eric A. Adams 530,725 0.31%
Horizons ETFs Management (Canada), Inc. 528,790 0.31%
IBI Mutual Funds Management (1978) Ltd. 221,410 0.13%
Alexandra D. J. Mancini 200,000 0.12%
Martin Bott 100,000 0.058%
Bruce S. Colwill 50,000 0.029%
Eric C. Hsu 42,000 0.024%
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
INMED PHARMACEUTICALS INC.-12.77%27
GILEAD SCIENCES20.36%94 124
VERTEX PHARMACEUTICALS8.84%61 693
REGENERON PHARMACEUTICALS31.38%53 154
WUXI APPTEC CO., LTD.1.90%21 017
GENMAB A/S-6.88%13 229
BEIGENE, LTD.-15.55%9 553
HUALAN BIOLOGICAL ENGINEERING INC.5.55%9 494
NEUROCRINE BIOSCIENCES, INC.-20.20%7 988
SAREPTA THERAPEUTICS, INC.-27.45%7 608
ARGENX SE-14.62%5 784
ASCENDIS PHARMA A/S-19.49%5 376
EXELIXIS, INC.-6.24%5 259
REATA PHARMACEUTICALS, INC.-36.97%4 796
ACCELERON PHARMA INC.52.36%4 793
FORTY SEVEN, INC.142.47%4 595
PEPTIDREAM INC.0.80%4 406
SPARK THERAPEUTICS, INC.0.00%4 375
BIOCON LIMITED-2.68%4 250
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.-13.22%4 153
ZAI LAB LIMITED23.95%3 813